Infigratinib Phosphate is a potent, selective FGFR1-3 tyrosine kinase inhibitor primarily indicated for the treatment of patients with unresectable, locally advanced or metastatic cholangiocarcinoma harboring… Read more



Infigratinib Phosphate is a potent, selective FGFR1-3 tyrosine kinase inhibitor primarily indicated for the treatment of patients with unresectable, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 gene rearrangements. As this compound is utilized in targeted oncological therapy, pharmaceutical laboratories rely on high-quality analytical tools to ensure therapeutic precision. This category provides comprehensive reference standards for Infigratinib Phosphate, including its known process-related impurities, potential degradation products, and metabolites. These compounds are essential for rigorous impurity profiling, method validation, and routine quality control protocols. Furthermore, the inclusion of stable isotope labelled standards enables accurate quantification and reliable pharmacokinetic studies, supporting the development and regulatory compliance of this medication. Laboratories utilizing these reference materials can maintain high standards of analytical accuracy throughout the drug lifecycle.